SCOPPITO (ITALPRESS) – Sanofi presented in its global smart factory of Scoppito the Impatto Report 2024, realized with the collaboration of KPMG Italia, on the occasion of the meeting “The impact of pharmaceutical innovation for the competitiveness and growth of the country: the excellence of Sanofi in Scoppito”. On this occasion, representatives of the institutions, the economic world and the territory discussed how to strengthen the national ecosystem of innovation in Life Sciences, seizing national and European opportunities and developing models of public-private collaboration capable of supporting the transformation of the sector and to drive development and competitiveness of the country. In the centre, the innovative trajectory of the Scoppito site, a high-tech bio-pharmaceutical manufacturing hub: a concrete example of how integration between technologies and artificial intelligence, skills of the future and immunological vocation can accelerate access to transformative therapies, while generating qualified employment and greater competitiveness for the country. The meeting was sponsored by the Senate of the Republic. “In investing in health and pharmaceutical innovation means investing in the future of the territories, especially the internal ones, which can become sustainable and cutting-edge development laboratories – said Guido Liris, President of the Intergroup parliamentary areas, mountain municipalities and smaller islands, Senate Budget Commission –. The reality of Sanofi in Scoppito shows how pharmaceutical innovation can result in real growth, employment and well-being. Our commitment to Parliament is to ensure that these trajectories of innovation are sustainable from the economic and financial point of view and capable of reducing territorial differences, bringing added value to the entire country. On the economic front, the study shows that only in 2024, the total contribution (direct, indirect and induced) of the company to the national economy was 505 million euros, equal to 0.02% of GDP. In addition, Sanofi’s activities have activated 4.184 jobs, of which 1,446 were directed, 2.150 throughout the supply chain and 588 in the pipeline. This means that for each employee occupied by Sanofi there is a multiplier effect of about 2 more people employed in our country. The employment of labour force also determines a significant distribution of income to households, totalling EUR 195 million in wages and salaries, considering the direct, indirect and induced effects. Compared to its people, in order to face the challenges of an ever-changing global scenario, the company has invested 1,6 million euros in Italy in training, providing over 81,500 hours of training. This is equivalent to an average of 56 hours per employee, with an estimated generated value of 3.8 million euros of benefit expected for employees. “Based on the Sanofi Italy Impact Report realized together with KPMG, for each euro invested in research, excellent manufacturing and expertise, almost 3 euros of total benefit for the community are generated – commented Marcello Cattani, Chairman and CEO, Sanofi Italia and Malta -. In 2024 the total contribution (direct, indirect and induced) generated by us on the Italian economy was 505 million euros. Our commitment to innovation therefore results in growth and health, in collective well-being and value for the Italian System and Europe all. Addressing us to the totality of the interlocutors who represent the ecosystem of health that produces innovation thanks to science, technology and AI, and generates value through clinical and industrial research, we want to put to common factor this analysis so that it becomes an example and open tool of comparison, stimulus and inspiration for the definition and realization of an innovative Italian Strategy for Life Sciences, as Italy deserves.” For Fausta Bergamotto, Undersecretary of the Ministry of Enterprises and Made in Italy, “Le Scienze della Vita constitute a fundamental motor of competitiveness and attraction of investments, in a global context in which the competition is increasingly intense. Not by chance, within the framework of the New Industrial Strategy, which will be illustrated in the White Paper of next publication, the pharmaceutical and biomedical are recognized among the priority areas on which to build the strengthening of the Italian production system, as capable of combining innovation, qualified employment and national security. The experience of Abruzzo, with excellence like the Sanofi factory in Scoppito, strengthens the role of Italy in the European landscape of Life Sciences”. The aim of Sanofi is to become the global biopharmaceutical company in immunology by 2030. Aware of the fundamental role played by innovation, in 2024 Sanofi in Italy invested €45.2 million in research and development. Considering also the costs avoided for the National Health System resulting from these activities, the overall impact generated is 133 million euros. Therefore, the direct expenses incurred generate a leverage effect of approximately 2,95, that is for each euro invested by Sanofi, the SSN realizes a total advantage of almost 3 euros. In this area, a key role is played by public-private partnerships, thanks to which Sanofi supports research projects, as innovative doctorates in areas with a high strategic impact on health. With his clinical research activity Sanofi, he explains a note, “contributes to consolidate the role of Italy as a scientific geography of excellence, promoting collaboration between institutions, universities and enterprises. The company’s commitment to immunology, neurology, oncology, rare diseases and prevention has generated tangible impacts for patients and SSN, demonstrating how innovation, in addition to improving health, represents a strategic investment for the competitiveness of the country. Precisely Scoppito will be more and more a reference center for industrial research of the company, where science takes shape and becomes production. Active since 1972 and specialized in the production of large-scale oral solid drugs, the Scoppito site is today the symbol of how science can translate into advanced manufacturing, digital technology and sustainable development. Here small molecules are produced to transform the approach to diseases with high social impact. Between 2020 and 2022 – we read again – Sanofi has implemented an investment plan on the site for almost 50 million euros, to which more than 7.3 million euros are added in 2024, to enhance productive capacity, safety and sustainability. The heart of this transformation is the Columbus High Potent Workshop, a completely digitized new generation department, in which augmented reality, real-time data and predictive models “Formula 1” – developed in collaboration with McLaren Racing – allow to significantly reduce the time of scale-up industrial, i.e. the transition from research to large-scale production. This approach, which integrates AI and human know-how, makes Scoppito one of the central sites in the world for the transformation of the results of research into therapies accessible to patients in rapid times, confirming the strategic role for the competitiveness of the global production network of Sanofi, a global centre of excellence and a strategic engine for the entire chain of Life Sciences in Italy”. Finally, Sanofi is also committed to environmental sustainability. In line with the global strategy – which aims at carbon neutrality by 2030 and zero emissions by 2045 – the company in Italy is actively involved in the protection of the planet. Its production sites have defined roadmaps to drive decarbonization of activities, implementing initiatives to reduce energy impact – such as the purchase of 100% electricity certified by renewable sources – and efficiency of consumption. These actions led to a reduction of CO2 emissions of -37% for the Anagni site and -34% for the Scoppito site compared to 2019, confirming the alignment to the roadmap defined by the Group, which provides a reduction of -55% by 2030. The efficiency of consumption and the use of energy from renewable sources translate into a benefit of 1.9 million euros of costs avoided for the environment and the community since 2019. Moreover, from the beginning of 2026 a photovoltaic system of 100,000 square meters will be operating, designed to provide renewable energy to the plant of Anagni.
– photo press Apco for Sanofi –(ITALPRESS).
